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ImmunoproteasomeForestomach tumors are observed inmice exposed to environmental carcinogens. However, the relevance of this
data to humans is controversial because humans lack a forestomach. We hypothesize that an understanding of
earlymolecular changes after exposure to a carcinogen in the forestomachwill providemode-of-action informa-
tion to evaluate the applicability of forestomach cancers to human cancer risk assessment. In the present study
we exposed mice to benzo(a)pyrene (BaP), an environmental carcinogen commonly associated with tumors of
the rodent forestomach. Toxicogenomic tools were used to proﬁle gene expression response in the forestomach.
Adult Muta™Mouse males were orally exposed to 25, 50, and 75 mg BaP/kg-body-weight/day for 28 consecutive
days. The forestomach was collected three days post-exposure. DNA microarrays, real-time RT-qPCR arrays, and
protein analyses were employed to characterize responses in the forestomach. Microarray results showed altered
expression of 414 genes across all treatment groups (±1.5 fold; false discovery rate adjusted P ≤ 0.05). Signiﬁcant
downregulation of genes associatedwith phase II xenobiotic metabolism and increased expression of genes impli-
cated in antigen processing and presentation, immune response, chemotaxis, and keratinocyte differentiation
were observed in treated groups in a dose-dependent manner. A systematic comparison of the differentially
expressed genes in the forestomach from the present study to differentially expressed genes identiﬁed in
human diseases including human gastrointestinal tract cancers using the NextBio Human Disease Atlas showed
signiﬁcant commonalities between the two models. Our results provide molecular evidence supporting the use
of the mouse forestomach model to evaluate chemically-induced gastrointestinal carcinogenesis in humans.
Crown Copyright © 2013 Published by Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
A review of the Carcinogenic Potency Database (http://toxnet.nlm.
nih.gov/cpdb/) and the USNational Cancer Institute/National Toxicology
Program (http://ntp-server.niehs.nih.gov) databases reveals that expo-
sure to approximately 120 different substances results in the develop-
ment of cancerous lesions in the rodent forestomach (Proctor et al.,BaP, benzo(a)pyrene; BPDE,
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ier Inc. Open access under CC BY-NC-2007). Indeed, the forestomach is a target for carcinogenesis in rodents
following oral exposure to various environmental chemicals. However,
the human health relevance of this type of cancer is unclear because
humans lack a forestomach (Proctor et al., 2007).
Anatomically, the rodent forestomach exhibits similarities to both
the human esophagus and stomach. Detailed analyses of cancers of
the forestomach reveal that these tumors are initiated by hyperplasia
of the forestomach squamous epithelial cells that form preneoplastic
lesions (Fukushima et al., 1997). These lesions progress into benign
papillomas and metastatic carcinomas over time, which histologically
resemble squamous cell carcinomas of the human esophagus (Nyrén and
Adami, 2002), stomach (Callery et al., 1985), colon (Landau et al., 2007),
and anal canal (Szmulowicz and Wu, 2012). However, forestomach
tumors are strictly of squamous cell origin, whereas esophageal cancers
can also originate from glandular columnar epithelial cells in the form
of adenocarcinomas, suggesting multiple mechanisms in the develop-
ment of esophageal tumors in humans (Proctor et al., 2007). In addition,
more than 95% of human stomach cancers are adenocarcinomas that
originate from glandular columnar epithelial cells or poorly differen-
tiated cells (Tsukamoto et al., 2007), and are thus distinct from rodent
forestomach tumors (Proctor et al., 2007). Although there appear to
be some fundamental differences between the aforementioned tumor
types, it seems reasonable to contend that the molecular initiatingND license.
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stomach share commonalities. A detailed and systematic characteri-
zation of the carcinogenic modes of action in the rodent forestomach
will provide an improved context for evaluating the biological rele-
vance of rodent forestomach tumor data for human health risk
assessment.
Benzo(a)pyrene (BaP), a known human carcinogen (IARC, 2012), is
a polycyclic aromatic hydrocarbon (PAH) that is produced during the
incomplete combustion of organic materials from various sources in-
cluding wood and tobacco smoke, vehicle exhaust, residential heating,
electric power, and cooking. Human exposure to BaP occurs primarily
through oral consumption of BaP-containing foods (Hettemer-Frey
and Travis, 1991). BaP requires metabolic activation by members of
the cytochrome P450 family of enzymes, which can generate several
DNA-reactive metabolites including BaP-7,8-dihydrodiol-9,10-epoxide
(BPDE). These metabolites are capable of forming covalent adducts
with proteins andDNA. If left unrepaired, DNA damage can causemuta-
tions leading to impaired gene function. We and others have demon-
strated the formation of DNA adducts following exposure to BaP in a
variety of tissues, including the gastrointestinal tract (Lemieux et al.,
2011), which is a primary site of contact following oral gavage, and
also in distant organs, such as the lungs and liver (Halappanavar et al.,
2011; Labib et al., 2012; Malik et al., 2012). In experimental animals,
exposure to BaP via feed or gavage predominantly and consistently
leads to the development of squamous cell papillomas in the fore-
stomach that primarily originate from the epithelial cell lining (Culp
et al., 1998; Wester et al., 2012). Although genotoxicity is the primary
mode of action of BaP in virtually all tissues, we previously used
toxicogenomics to demonstrate that the nature and extent of molecular
responses at the gene and protein level are somewhat different between
tissues (Halappanavar et al., 2011; Labib et al., 2012; Malik et al., 2012;
Yauk et al., 2011). For example, a comparison of gene expression proﬁles
in mouse lung and liver following acute BaP exposure (i.e. 150 or
300 mg/kg-body-weight/day by oral gavage for 3 days) revealed
broad commonalities, including the activation of pathways involved in
oxidative stress, xenobiotic metabolism, AhR signaling, and the DNA
damage response (Halappanavar et al., 2011). However, signiﬁcant in-
hibition of B-cell receptor signaling was a predominant perturbation
uniquely found in the lungs of BaP-exposed mice (Halappanavar et al.,
2011). In addition, the magnitude of the overall transcriptional
response (fold changes and the total number of genes) is much greater
in the lungs than in the liver. We also recently demonstrated that DNA
adduct levels are higher in the lungs of BaP treated mice as compared
with the liver, but that mutation frequencies in these two tissues are
quite similar (Labib et al., 2012). In alignment with our ﬁndings, Uno
et al. (2004) showed tissue-speciﬁc roles of Cyp1a1 using Cyp1a1
knockout mice. These authors showed that Cyp1a1 expression in the
intestine plays an important role in detoxiﬁcation, whereas Cyp1a1
activation in the liver is associated with DNA damage-induced liver
carcinogenesis (Uno et al., 2004). These studies collectively demonstrate
that although genotoxicity is a primary component of themode of action
of BaP-mediated carcinogenesis, differences in the underlying molecular
responses to BaP likely contribute to the observed tissue-speciﬁcity
during tumorigenesis.
The present study employed genomic and bioinformatic tools to
identify early molecular initiating events that contribute to tumorigen-
esis in the forestomach, with the overarching objective of exploring the
biological relevance of forestomach tumors for human health risk
assessment. More speciﬁcally, we employed global gene expression
proﬁling of forestomach tissue from mice exposed to BaP at doses
that are known to induce tumors in the mouse forestomach (Culp
et al., 1998). Adult male Muta™Mouse were exposed to 25, 50, and
75 mg/kg-bw/day of BaP for 28 consecutive days via oral gavage,
and the top dose has previously been shown to cause squamous
cell carcinomas, papillomas, and hyperplasia in the forestomach
(Hakura et al., 1998). Mice were sacriﬁced 3 days after the lastexposure. Global transcription response was analyzed in detail in
order to identify the expression changes in biological pathways associ-
ated with cancer formation in the forestomach. BaP-induced gene ex-
pression proﬁles were compared with transcriptomic proﬁles of
human diseases (e.g., human gastrointestinal tract cancer) using the
NextBio Human Disease Atlas.
Methods
Animal treatment. Mouse exposures and sample collection proce-
dures are described in detail previously (Labib et al., 2012; Lemieux
et al., 2011; Malik et al., 2012). The Muta™Mouse contains around
29 +/− 4 copies of λgt10lacZ shuttle vector, a non-transcribed insert,
stably integrated in the mouse genome (Shwed et al., 2010), thus
permitting in vivo lacZ mutant frequency analysis. The transgenic in-
sert, which contains lacZ, is employed as an in vivo mutation target.
Brieﬂy, 25-week old male Muta™Mouse were individually housed in
plastic ﬁlm isolators, providedwithwater and food (2012 Teklad Global
standard rodent diet) ad libitum, and were subjected to a 12 h light/
12 h dark cycle. Mice were divided into four experimental groups
consisting of 5 animals each: 0 (control), 25 (low dose), 50 (medium
dose) and 75 (high dose) mg/kg-bw/day of BaP (Sigma-Aldrich, Oakville,
ON, Canada) dissolved in olive oil. Mice were exposed daily by oral
gavage for 28 consecutive days. The control group received only olive
oil, the vehicle control. We acknowledge that the doses used in the
present study are high compared to the expected daily intake of
BaP via food in the United States (Hattemer-Frey and Travis, 1991).
However, these high doses permit a toxicogenomic investigation of
toxicological mechanisms underlying BaP-induced effects at much
early post-exposure time points. The animals were sacriﬁced by cardiac
puncture under isoﬂuorane anesthesia on day 3 following the last expo-
sure. The forestomach was excised, ﬂash-frozen in liquid nitrogen, and
stored at−80 °C. Care and maintenance of themice in this experiment
were approved by the Health Canada Animal Care Committee.
Tissue RNA extraction and puriﬁcation. Total RNA was isolated from
a random section of the forestomach tissue as described in Labib et al.
(2012). In brief, a small random section of the mouse forestomach was
homogenized immediately in TRIzol reagent (Invitrogen, Carlsbad, CA,
USA) using the Retsch Mixer MM 400. The RNA was isolated using
chloroform and precipitated using isopropyl alcohol. The RNA was
subsequently puriﬁed using RNeasyMini Plus kits (Qiagen,Mississauga,
ON, Canada). All RNA samples showed anA260/280 ratio between 2.0 and
2.2, and an A260/230 ratio between 1.7 and 2.3. The integrity of the RNA
sampleswas analyzed using an Agilent 2100 Bioanalyzer (Agilent Tech-
nologies, Mississauga, ON, Canada). All samples had an RNA integrity
number above 6.6 and were all used for microarray analysis.
Microarray hybridization and analysis. Total RNA (200 ng) from
each individual mouse forestomach sample in each treatment group
and Universal Mouse Reference RNA (UMRR, Stratagene, Mississauga,
ON, Canada) was used to synthesize cDNA and cyanine-labeled cRNA
using the Agilent Linear Ampliﬁcation Kit (Agilent Technologies Inc.,
Mississauga, ON, Canada). Cyanine-labeled cRNA was in vitro tran-
scribed using T7 RNA polymerase and puriﬁed using RNeasy Mini Kits
(Qiagen, Mississauga, ON, Canada); experimental samples were labeled
with Cyanine-5 and the UMRR was labeled with Cyanine-3. 300 ng of
labeled cRNA from each experimental sample was hybridized with the
same amount of labeled reference RNA to Agilent Sureprint G3 Mouse
GE 8x60K microarrays (Agilent Technologies Inc., Mississauga, ON,
Canada) at 65 °C overnight (17 h) in the Agilent SureHyb hybridization
chamber. The arrays were washed and scanned on an Agilent G2505B
Scanner according to the manufacturer's recommendations. Data were
extracted using Feature Extraction 10.7.3.1 (Agilent Technologies, Inc.,
Mississauga, ON, Canada).
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ment (R-Development-Core-Team, 2010). Brieﬂy, the background ﬂuo-
rescence was measured using the negative control 3xSLv1 probes;
probes with median signal intensities less than the trimmed mean
(trim = 5%) plus three trimmed standard deviations of 3xSLv1 probe
were ﬂagged as absent (i.e. within the background signal). Probes were
considered present if at least four of the ﬁve samples within a condition
had signal intensities greater than three trimmed standard deviations
above the trimmed mean of the 3xSLv1 probes (background signal).
Data were normalized using LOWESS (Yang et al., 2002), and ratio
intensity plots and heat maps for the raw and normalized data
were constructed to identify outliers. Three samples were removed
from the analysis based on clustering (one sample in each of the
25, 50, and 75 mg/kg-bw/day dose groups). The ﬁnal sample size
consisted of n = 5 in control, n = 4 in 25 mg/kg-bw/day, n = 4 in
50 mg/kg-bw/day, n = 4 in 75 mg/kg-bw/day groups. Differentially
expressed transcripts (upregulated or downregulated relative to the
olive oil treated control mouse forestomach) were determined using
the MAANOVA library in R. The statistical model included the ﬁxed
effects slide and treatment condition, and was applied to the log2
of the relative intensities. The Fs statistic (Cui et al., 2005) was
used to test for treatment effects. The P values for all statistical
tests were estimated by the permutation method using residual
shufﬂing, followed by adjustment for multiple comparisons using
the false discovery rate (FDR) approach (Benjamini and Hochberg,
1995). The fold change calculations were estimated as described previ-
ously (Malik et al., 2012). Signiﬁcant genes were selected based on
FDR-adjusted P value (FDR P) ≤ 0.05 for any BaP exposed versus control
contrast. All microarray data have been deposited in the NCBI Gene
ExpressionOmnibus database and can be accessed through the accession
number GSE43438.
Bioinformatic and pathway analysis. Following microarray normali-
zation, all genes that passed the FDR P ≤ 0.05 and fold change ≥ 1.5
cut-off were considered for further analysis using various bioinfor-
matic and pathway analysis tools to identify the biological functions
or processes in the forestomach perturbed in response to BaP. The
Database for Annotation, Visualization, and Integrated Discovery
(DAVID) (Huang da et al., 2009a, 2009b) Functional Annotation
Tools (clustering and charts) were used to identify Gene Ontology
(GO) terms associated with the differentially expressed gene list.
Genes signiﬁcantly differentially expressed in each of the signiﬁcant
clusters were plotted on polar plots using SigmaPlot for Windows
version 12.0 build 12.0.0.182. In addition to the functional classiﬁcation,
DAVID was used to visualize the differentially expressed genes in the
Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways. The
biological and molecular functions of the signiﬁcantly differentially
expressed genes following BaP treatment in the forestomach were
further analyzed and explored in Ingenuity Pathway Analysis (IPA,
Ingenuity Systems, Redwood City, CA, USA) and MetaCore (Thomson
Reuters, http://www.genego.com/metacore.php). The signiﬁcance of
the association between the dataset and the canonical pathways and
functions in IPA was measured using the Fisher's exact test. IPA
Upstream Regulator Analysis was used to identify the cascade of up-
stream transcriptional regulators that explain the observed gene ex-
pression changes in the forestomach. Only regulators with a Z-score
above 2.0 were considered in this analysis. MetaCore process networks
identiﬁed the networks associated with GO processes that were most
signiﬁcant in this dataset.
Mining of public databases for human disease correlation. All statisti-
cally signiﬁcant and differentially expressed genes from all dose
groups were mined against the genomic data repositories in NextBio
(http://nextbio.com). Disease prediction was performed using the
75 mg/kg-bw/day dose group. Data were compared to curated
datasets available in NextBio to identify published studies of diseaseswith similar gene proﬁles, gene ranking, and consistency in fold change
directionality. Pairwise gene signature correlations and rank-based
enrichment statistics were employed to calculate the NextBio scores
for each disease. The disease that ranked the highest in comparison
withBaP exposurewas given a score of 100 and the restwere normalized
accordingly. The meta-analysis function was used to compare the signif-
icantly differentially expressed genes associated with the most enriched
gene ontologies from the BaP exposed forestomach to 59 gastrointestinal
tract cancer biosets from curated databases available in NextBio (Supple-
mentary Table 1), including esophageal cancers, gastric cancers, intestinal
cancers, and colon cancers.
Quantitative real time (qRT)-PCR array validation. Eighty-four genes
were selected for further validation by quantitative real-time RT-qPCR
using custom RT2 Proﬁler PCR Arrays and a BioRad CFX96 real-time
PCR detection system. Genes were selected based on their statistical
signiﬁcance, and their relevance to biological phenomena of interest
and relevance to the project. A custom RT2 Proﬁler PCR Array plate, the
RT2 First Strand Kit and RT2 SYBR® Green qPCR Mastermix (QIAGEN
Sciences, Maryland, USA) were used. Reference genes for normalization
were selected based on their stable expression levels in the treated and
control samples. Ct values for each gene were normalized to actin β
(Actb) and glyceraldehyde 3-phosphate dehydrogenase (Gapdh), the
most stable reference genes. A threshold value was set to 102. Only
samples that were included in the microarray analysis were used for
validation. Furthermore, an additional 2 samples (one in each of the
50 and75 mg/kg-bw/daydose groups)were removedbased on improper
clustering. Given this criteria, the ﬁnal validation group consisted of
sample size of n = 5 in control, n = 4 in 25 mg/kg-bw/day, n = 3 in
50 mg/kg-bw/day, n = 3 in 75 mg/kg-bw/day groups.
Western blot analysis. Total protein from the frozen mouse fore-
stomach experimental and control tissues was extracted using
Bio-Plex Cell Lysis Kits (BioRad Laboratories, Mississauga, ON, Canada)
containing a protease inhibitor cocktail (1:200) (Sigma-Aldrich,
Oakville, ON, Canada) and a phosphatase inhibitor cocktail (PhosSTOP,
ROCHE, Laval, QC, Canada). Total protein was quantiﬁed using a Bradford
protein assay kit (BioRad Laboratories, Mississauga, ON, Canada).
30–50 μg of total protein was run on 4–15% SDS/PAGE gels (BioRad
Laboratories, Mississauga, ON, Canada) and was transferred onto a
polyvinylidene ﬂuoride membrane (Millipore, Billerica, MA, USA) by
wet transfer for 1 h at 100 V. Anti-proteasome 20S LMP2 (1 μg/ml;
Abcam Inc., Toronto, ON, Canada) and anti-MECL-1 (E20) (1:200;
Santa Cruz Biotechnology, Dallas, TX, USA) antibodies were used to
test for immunoproteasome activation. Anti-20S proteasome β1
(FL-241) (1:200; Santa Cruz Biotechnology) and anti-proteasome 20S
β2 subunit (MCP165) (1:1000; Enzo Life Sciences, Brockville, ON,
Canada) were used to monitor changes in proteasome composition.
All expression values were normalized relative to β-actin (1:2500;
Cell Signaling Technologies, Danvers, MA, USA) in Image Lab software
version 4.1 build 16 (BioRad Laboratories, Mississauga, ON, Canada).
Results
Daily exposure to 25, 50, and 75 mg/kg-bw/day BaP for 28 consecu-
tive days elicited no overt signs of toxicity and there was no signiﬁcant
loss in body weight for any of the exposed mice compared to
vehicle-treated controls (Lemieux et al., 2011).
General overview of forestomach gene expression proﬁles
Repeated oral gavage with BaP induced signiﬁcant changes in the
expression of many genes in the forestomach. MAANOVA analysis re-
vealed a total of 497 probes associatedwith 414 speciﬁc genes differen-
tially expressed (up- or down-regulated) with a fold change ≥ 1.5 in
either direction, and an FDR P ≤ 0.05 in at least one treatment group
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and 487 unique probes associated with 9, 135, and 408 unique
genes were signiﬁcantly differentially expressed in the 25, 50, and
75 mg/kg-bw/day dose groups, respectively (Supplementary Fig. 1).
Hierarchical cluster analysis of all signiﬁcant, differentially expressed
genes (FDR P ≤ 0.05 and fold change ≥ 1.5) revealed that the treatment
groups clustered separately from controls, thus a clear treatment effect
was observed as a result of exposure to BaP (Supplementary Fig. 2).
Biological function and pathway analysis of signiﬁcantly differentially
expressed genes
GO and pathway analyses were employed to assign biological pro-
cesses and functional categories to genes whose expression was signiﬁ-
cantly affected by BaP in DAVID, KEGG, IPA, and MetaCore.
Using the functional annotation tool in DAVID, signiﬁcantly differen-
tially expressed geneswere categorized into speciﬁc biological processes,
cellular compartments, and molecular functions. The resulting clusters
consisting of GO terms were sorted based on DAVID enrichment score
and were considered signiﬁcant only if they exhibited Benjamini-
corrected P ≤ 0.05 (Fig. 1). With this cut-off, four main GO clusters
were identiﬁed: antigen processing and presentation [GO:0019882],
immune response [GO:0006955], chemotaxis [GO:0006935], and
epithelial cell differentiation [GO:0030855]. Each of these biological
processes was further expanded to identify the extent of enrichment
and coverage.
The immune response classiﬁcation consisted of 27 and 45 genes
in the 50 and 75 mg/kg-bw/day dose groups, respectively, and was
represented by defense response [GO:0006952], immune response
[GO:0006955], and response to virus [GO:0009615]. The antigen
processing and presentation classiﬁcation was enriched with a total
of 3, 14, and 40 genes in the 25, 50, and 75 mg/kg-bw/day dose groups,
respectively. Within this classiﬁcation, processes such as antigen pro-
cessing and presentation via major histocompatibility complex (MHC)Fig. 1. Step-wise organization of the most signiﬁcant Gene Ontology processes perturbed in
antigen processing and presentation to epithelial cell differentiation. Polar plots show the fold
category (red circle) subdivided into individual pathways/networks associated with the gen
lines and circles indicate response in 25 mg/kg-bw/day, blue in 50 mg/kg-bw/day, and red inclass I [GO:0002474], response to virus [GO:0009615], cell surface
[GO:0009986], antigen processing and presentation [GO:0019882],
MHC protein complex [GO:0042611], MHC class I protein complex
[GO:0042612], antigen processing and presentation of peptide antigen
[GO:0048002] were over represented. The epithelial cell differentiation
consisted of 10 and 19 differentially expressed genes in the 50 and
75 mg/kg-bw/day dose groups, respectively, and was enriched
with GO terms such as corniﬁed envelope [GO:0001533], ectoderm
development [GO:0007398], epidermis development [GO:0008544],
epidermal cell differentiation [GO:0009913], keratinocyte differenti-
ation [GO:0030216], epithelial cell differentiation [GO:0030855],
keratinization [GO:0031424], intermediate ﬁlament-based process
[GO:0045103], intermediate ﬁlament cytoskeleton organization
[GO:0045104], and epithelial development [GO:0060429]. Lastly,
the chemotaxis classiﬁcation was associated with 2, 5, and 24 genes in
the 25, 50, and 75 mg/kg-bw/day dose groups, respectively, and was
represented by chemotaxis [GO:0006935], inﬂammatory response
[GO:0006954], chemokine activity [GO:0008009], response towounding
[GO:0009611], taxis [GO:0042330], and chemokine receptor binding
[GO:0042379]. Detailed analysis of the entire list of differentially
expressed genes implicated in these processes revealed a toxic response
gradient involving activation of immune response and inﬂammation,
thus reﬂecting a host defense response to BaP exposure. Induction of
the keratinization process was observed primarily in the high dose
group and is suggestive of activation of cellular transformation processes
normally observed during carcinogenic transformation. Fig. 1 demon-
strates this gradual transition. GO clusters in Fig. 1 display genes associ-
ated with all child GO terms. Genes common to more than one GO
cluster are displayed with the most biologically relevant cluster.
Pathway analysis of all the differentially expressed genes in all
dose groups was conducted using KEGG pathways in DAVID, IPA
Canonical Pathways, and MetaCore Network Processes (Supplementary
Fig. 3). A total of seven KEGG pathways showing a signiﬁcant (Benjamini
corrected P ≤ 0.05) enrichment according to DAVID, ten IPA canonicalthe BaP-exposed forestomach showing dose-dependent transition in the response from
changes associated with the signiﬁcantly differentially expressed genes in each ontology
es (orange rectangles). Arrows indicate causal relationships between categories. Green
75 mg/kg-bw/day dose groups.
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were signiﬁcantly enriched in at least two treatment groups (Sup-
plementary Fig. 3). Unique pathways in each dose group included
inﬂammation-related signaling at the 25 mg/kg-bw/day dose group, nat-
ural killer T (NKT) cell mediated cytotoxicity at the 50 mg/kg-bw/day
dose group, and p53 signaling and glutathione metabolism at the
75 mg/kg-bw/day dose group. Supplementary Fig. 3 shows all of the
pathways identiﬁed using each analysis tool.
Detailed analysis in IPA revealed that all of the differentially
expressed genes and the associated biological processes are regulated
by a ﬁnite number of upstream regulators, including cytokines, tran-
scriptional factors, kinases, and receptors (Supplementary Table 3).
The primary upstream regulator was interferon γ (IFNγ), which is a
cytokine with immunoregulatory properties. IFNγwas associated with
69 differentially expressed genes in our dataset, and the expression
proﬁles of these genes reﬂect IFNγ activation (Fig. 2). The analysis
also revealed the inhibition of the transcriptional regulator tripartite
motif containing 24 (Trim24), which is associated with 28 differentially
expressed genes, and p53, which is associated with 21 genes.
Disease prediction
In order to identify the expression patterns in the BaP-exposed
forestomach that may be relevant to human diseases, differentially
expressed genes from the 75 mg/kg-bw/day BaP dose group were
analyzed using the NextBio Human Disease Atlas. This analysis
revealed bacterial infectious diseases, respiratory disorders, parasitic
diseases, and viral infectious diseases as the top four human diseases
correlated with mouse BaP exposed forestomach expression proﬁles
(Supplementary Table 4). Cancer was the 18th most correlated disease,
supported by 641 studies. We then queried all of the signiﬁcant genes
(FDR P ≤ 0.05 and fold change ≥ 1.5) in the BaP-treated forestomach
associated with antigen processing and presentation, immune re-
sponse, chemotaxis, and keratinocyte differentiation against curatedFig. 2. (A) Graphical representation of upstream regulators and the signiﬁcantly differentia
Regulator analysis. The IFNγ, P53, and NFκB regulators were selected for their relative sign
Network (IPA) analysis of activated and inhibited regulators signiﬁcant in the BaP expose
lines indicate indirect interaction.studies in NextBio related to human esophageal (score 60), gastric
(score 15), intestinal (score 64), and colon (score 38) cancers. Several
genes associated with the aforementioned top GO processes were
common between the BaP exposed forestomach responses and the
aforementioned types of human cancers (Table 1), suggesting strong
similarity between gene expression in the BaP-exposed rodent
forestomach and various human cancers.
qRT-PCR validation of representative genes
A total of 84 genes were validated using RT-qPCR arrays (Supple-
mentary Table 5). These genes included: (a) 54 involved in antigen pro-
cessing and presentation, immune and inﬂammatory response, and
keratinocyte differentiation; (b) seven involved in xenobiotic metabo-
lism; (c) eight involved in DNA damage response; (d) three growth
factors; and (e) 12 genes showing the highest fold changes.
Fifty six of the 84 genes were differentially expressed with P ≤ 0.05
in at least one treatment group compared tomatched controls (Table 2)
including: 16 related to antigen processing and presentation, 14 in the
immune and inﬂammatory processes, 14 involved in keratinocyte dif-
ferentiation, six in DNA damage response pathways, and six involved
in xenobiotic metabolism. Three genes showed statistically signiﬁcant
differential expression by RT-qPCR, but not by microarrays. These
includedmurine double minute 2 (Mdm2), C-type lectin domain family
2 member g (Clec2g), and amphiregulin (Areg).
Protein validation
In addition to the changes described above, our gene expression
analysis also revealed distinct upregulation of immunoproteasome
subunits. Speciﬁcally, proteasome subunit beta type 9 (Psmb9: 2.8 and
3.5-fold change in 50 and 75 mg/kg-bw/day dose groups, respectively)
and 10 (Pmb10: 1.6 and 1.5-fold change in 50 and 75 mg/kg-bw/day
dose groups, respectively) were perturbed by oral BaP exposure.lly expressed genes associated with them. The graph was generated by IPA's Upstream
iﬁcance in the context of the dataset as determined by the Z-score. (B–D) Mechanistic
d forestomach showing interconnections between regulators in the gene set. Dashed
Table 1
Meta-analysis in NextBio of signiﬁcant genes in the BaP-treated mouse forestomach and human proﬁles in which esophageal, gastric, intestinal, or colon cancer was a phenotype.
Disease Antigen processing
and presentation a
# of
studiesb
Immune
response
# of
studies
Chemotaxis # of
studies
Keratinocyte
differentiation
# of
studies
Esophageal cancers B2M 3 Iﬁ35 8 Ccl11 2 Col11a1 (III) 7
H2-K1 4 Irf1 3 Ccl7 1 Krt17 6
H2-q10 6 Irf9 4 Ccl8 1 Trp63 5
H2-t23 2 Mx1 3 Ccr2 1
Nlrc5 2 Socs1 3 Cxcl10 3
Tap1 5 Stat2 4 Cxcl16 2
Psmb9 5 Tap1 5 Cxcl9 4
Psmb10 6 Clec3b 1 Stat2 4
Clec2f 1
Gastric cancers H2-q10 (IIIB) 1 Iﬁ35 1 Ccl8 4 Aldh1a3 6
H2-t23 2 Irf1 1 Cxcl10 5 Col11a1 5
Nlrc5 2 Irf9 1 Cxcl16 5 Krt17 7
H2-Aa (IIIB) 3 Socs1 2 Cxcl9 (IIIA, IIIB) 6 Krt6b 1
Tap1 (IB, IVA) 7 Stat2 (IIIB, IVA) 3 Il20ra 1 Sprr1b (IIIB) 2
Psmb9 3 Tap1 (IB, IVA) 7 Rasgrp2 1 Sprr2g (IIIB) 1
Clec3b (IIIB) 1 Stat2 (IIIB, IVA) 3 Trp63 (IIIB) 1
Tnsfrsf16 (IIIA, IIIB) 2
Intestinal cancers H2-Aa (IA, IIIA) 2 Irf9 1 Cxcl10 (IB, II, IIIA) 4 Agpat6 1
Tap1 (IA, IB, II, IIIA, IVA) 4 Mx1 (IB) 1 Cxcl16 (IB, II, IIIA, IIIB) 4 Col11a1 (IB, II, IIIB, IVA, IVB) 5
Stat2 (II, IIIA, IIIB) 4 Cxcl9 (IA, IB, II, IIIA, IIIB, IVA) 6 Krt17 (IB, II) 2
Tap1 (IA, IB, II, IIIA, IVA) 4 Stat2 (II, IIIA, IIIB) 4 Tbx3 (IB, IIIA) 3
Clec2f (IIIA, IVB) 2 Trp63 (IVB) 1
Clec10a (IA) 1
Colon cancer H2-K1 1 Irf1 4 Ccl11 2 Aldh1a3 8
H2-q10 4 Irf9 4 Ccl7 2 Col11a1 17
H2-t23 2 Mx1 6 Ccl8 1 Ddr1 3
Nlrc5 3 Socs1 9 Cxcl10 14 Krt17 11
H2-Aa 1 Stat2 2 Cxcl16 19 Krt6b 20
Tap1 7 Tap1 7 Cxcl9 12 Krt6a 10
Psmb9 8 Il20ra 12 Pou3f1 1
Rasgrp2 5 Sprr1b 2
Stat2 2 Sprr2a2 1
Tnfrsf11b 1 Sprr2d 2
Tnfrsf16 1 Tbx3 1
Trp63 1
a The genes listedwere signiﬁcantly differentially expressed (FDRP ≤ 0.05 and fold change ≥ 1.5) in our dataset and similarly differentially expressed in the curated studies inNextBio.
b The number of studies refers to the total number of studies used in the meta-analysis that are positively correlatedwith our dataset. The individual studies used in themeta-analysis
can be found in Supplementary Table 1.
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β2i, respectively, which are activated in place of the standard
proteasome subunits β1 and β2 (Ferrington and Gregerson, 2012)
under conditions of oxidative stress or IFNγ induction (Heink et al.,
2005). Since immunoproteasomeactivation is speciﬁc to thepresentation
ofMHC class I antigens, and since they are the upstream regulators of the
immune response pathways altered in the present study,we investigated
the biological relevance of the observed changes in Psmb9 and Psmb10
gene expression at the protein synthesis level. Western blot analysis
showed a dose-dependent increase in immunoproteasome subunits β1i
(from 1.7 to 3.6 fold) and β2i (from 1.9 to 4.6-fold) protein expression
relative to matched controls, respectively (Fig. 3). However, we saw no
change in subunits β1 and β2, the normal proteasome subunits,
suggesting speciﬁc BaP-induced activation of immunoproteasome in
the forestomach.
Discussion
We analyzed global gene expression proﬁles in the forestomach of
mice exposed to the genotoxic carcinogen BaP in order to explore the
molecular mechanisms associated with forestomach cancer. Mice
were exposed via oral gavage for 28 consecutive days to 25, 50 and
75 mg/kg-bw/day BaP. The top dose is known to induce forestomach
tumors in the mouse strain examined (Hakura et al., 1998). Systematic
analysis of all differentially expressed genes revealed three major
features: 1) activation of DNAdamage response pathways; 2) activation
of immune response including antigen presentation pathways and
immunoproteasome; and 3) potential for oncogenic transformation
reﬂected by induction of genes involved in keratinization in the highdose. We present results that delineate the molecular dynamics of
dose-dependent transitions in the response to BaP, explore the relevance
of the BaP-induced gene expression proﬁles to humandisease, andﬁnally,
discuss the applicability of rodent forestomach tumor data for human
health risk assessment.
BaP-induced DNA damage response in the forestomach
The most established mechanism underlying BaP-induced carcino-
genesis involves the metabolic activation of BaP, and subsequent inter-
action of BaP metabolites with DNA, leading to DNA adducts and
mutations in tumor suppressor genes or oncogenes (IARC, 2012).
However, rates of BaPmetabolism, levels of DNA adducts, andmutation
frequencies do not correlate with the extent of tumor formation in the
tissues studied (Godschalk et al., 2003), suggesting that additional
tissue-speciﬁc factors may contribute to carcinogenic events. Although
we did not directly measure DNA adducts in the forestomach, a pre-
vious study by our group did note a dose-dependent increase in DNA
adducts and lacZ mutant frequency in the glandular stomach of mice
exposed to BaP (Lemieux et al., 2011), and previous studies have
established that levels of DNA adducts in the glandular stomach
and forestomach from mice orally exposed to BaP for 24 h and ﬁve
days are comparable (Arlt et al., 2008). Although the ﬁnding of Arlt
et al. (2008) refers to acute exposure effects, it should be acknowledged
that the differences between the rate of cellular proliferation and the
metabolic capacity to form DNA-reactive BaP metabolites in the
forestomach and glandular stomach, could all inﬂuence the extent of
DNA damage and the outcome following 28 days of repeated exposure.
For instance, basal cellular proliferation rates, as determined by BrdU
Table 2
Genes validated by real-time PCR in the forestomach of BaP treated mice divided by
function. All genes shown were signiﬁcantly differentially expressed with a FDR
P ≤ 0.05 and fold change ≥ 1.5 in either direction. ↑ indicates upregulated; ↓ indicates
downregulated, and – indicates no change.
25 mg/kg/day
vs control
50 mg/kg/day
vs control
75 mg/kg/day
vs control
PCR
array
Microarray PCR
array
Microarray PCR
array
Microarray
Antigen processing and presentation
B2m – – ↑8.6 ↑2.1 ↑10.3 ↑3.1
Clec10a – – ↑5.4 ↑1.7 ↑5.8 ↑1.8
Clec2e – – ↑4.6 – – ↑1.9
Clec2g ↓2.5 – – – ↓7.8 –
Clec4a1 – – ↑8.2 – – ↑1.6
H2-Aa – – ↑2.5 – ↑2.8 ↑2.6
H2-DMb1 ↑1.9 – ↑4.7 – ↑8.7 ↑2.0
H2-K1 ↑2.1 – ↑3.2 ↑2.4 ↑3.7 ↑3.7
H2-M2 – – ↑7.5 ↑2.3 ↑2.7 ↑5.0
H2-Q7 ↑1.9 – ↑2.6 ↑2.2 ↑2.4 ↑3.2
H2-Q8 – – ↑7.2 ↑3.0 ↑12.3 ↑5.1
H2-T10 ↑2.6 – ↑7.4 ↑2.0 ↑11.6 ↑2.7
H2-T23 ↑1.7 – ↑5.3 ↑2.1 ↑6.6 ↑2.8
H2-T9 ↑1.9 – ↑3.6 ↑1.6 ↑3.9 ↑2.2
Klra15 – – ↑8.1 ↑1.6 – ↑1.7
Tap1 ↑3.9 – ↑11.1 ↑1.8 ↑7.6 ↑2.6
DNA damage response
Bst2 ↑2.1 – ↑3.0 ↑2.7 ↑5.3 ↑3.2
Mdm2 – – ↑1.9 – ↑3.3 –
Mgmt – – ↑2.3 ↑1.9 ↑3.1 ↑1.7
Pmaip1 ↑2.9 – ↑15.4 ↑1.8 ↑18.9 ↑2.1
Trp53inp1 ↑1.7 – ↑1.8 ↑1.7 ↑2.3 ↑1.8
Trp63 ↑1.6 – – – ↑1.4 ↑1.5
Immune/inﬂammatory response
Ccl11 – – ↑2.4 – ↑4.8 ↑1.8
Ccl12 ↑2.2 ↑2.0 ↑11.4 ↑2.1 ↑19.9 ↑2.8
Ccl7 ↑1.8 – ↑9.9 – ↑18.7 ↑1.8
Ccl8 ↑7.1 ↑6.6 ↑53.4 ↑13.8 ↑87.6 ↑16.7
Cxcl10 – – ↑8.9 ↑3.0 ↑17.2 ↑4.3
Cxcl16 – – – ↑1.4 ↑1.9 ↑1.6
Cxcl9 – – ↑6.4 – ↑10.8 ↑2.9
Iﬁ35 – – ↑2.3 ↑1.4 ↑2.9 ↑1.6
Irf1 – – ↑2.7 ↑1.9 ↑2.4 ↑1.8
Irf9 ↑1.8 – ↑5.1 ↑2.1 ↑7.8 ↑2.8
Isg15 ↑4.3 – ↑26.6 ↑4.6 ↑82.1 ↑8.8
Saa1 – – ↑3.7 ↓2.4 – ↓3.2
Saa2 – – – ↓3.0 ↓3.4 ↓4.4
Socs1 – – – – ↑2.6 ↑1.6
Keratinocyte differentiation
Areg – – ↑3.0 – ↑4.8 –
Gbp2 ↑1.9 – ↑12.3 ↑2.3 ↑4.7 ↑2.4
Klk14 – – ↑3.8 – ↑8.6 ↑2.5
Krt16 – – ↑2.3 ↑7.3 ↑2.4 ↑13.3
Krt6a – – – ↑3.2 ↑5.4 ↑4.5
Krt6b – – ↑12.0 ↑2.9 ↑24.1 ↑4.5
Oas1a – – ↑16.3 ↑5.1 ↑28.4 ↑8.9
Sprr1b – – ↑2.9 ↑3.7 ↑4.4 ↑8.5
Sprr2e – – ↑5.4 ↑2.0 ↑6.5 ↑2.4
Sprr2f – – ↑2.5 ↑3.0 ↑4.2 ↑7.2
Sprr2g – – – ↑2.7 ↑23.0 ↑4.6
Stfa1 – – – ↑9.9 ↑308.1 ↑78.5
Stfa2 ↑4.1 – ↑32.1 ↑4.4 ↑136.6 ↑15.5
Stfa2l1 – – ↑2.4 ↑2.8 – ↑11.4
Xenobiotic metabolism
Aldh1a3 ↑1.8 – ↑5.1 – ↑4.7 ↑1.8
Gsta1 – ↑1.9 ↑6.6 ↑2.1 ↑15.8 ↑2.5
Gsta2 – – ↑11.7 – – ↑2.0
Gstm4 – – ↑4.3 – ↑6.7 ↑1.5
Gsto1 – – ↑2.9 – ↑5.0 ↑1.6
Ugt2b34 – – ↓1.8 – ↓2.0 ↓3.1
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forestomach are approximately 50–67% that of the glandular stomach
(Shibata et al., 1990; Tanaka et al., 2011). While not the same endpoint,other studies have usedhyperplasia asmarker of increased cellular prolif-
eration, and have shown increased hyperplasia in the forestomach fol-
lowing BaP oral exposure. Other studies comparing cellular proliferation
rates after oral exposure to okadaic acid-like compounds (non-PAHs)
have shown higher proliferation levels in the forestomach compared to
the glandular stomach (Yuasa et al., 1994). These results imply that
upon stimulation by BaP for 28 consecutive days, cellular proliferation
could be expected to signiﬁcantly increase in the forestomach compared
to 24 h or ﬁve days of exposure. Another determinant of the potential
differences between the two tissues that plays an important role in the
DNA damage induced by BaP could be differences in phase I metabolism
by cytochrome P450 enzymes, which is necessary for the generation of
DNA reactive BaP metabolites, such as BPDE. Indeed, it has been shown
that, following ﬁve days of oral BaP exposure, the mRNA and protein
levels of Cyp1a1 and Cyp1b1 are higher in the forestomach compared
to the glandular stomach (Uno et al., 2008). In toto, we can reasonably
assert that following 28 days of repeated exposure, due, at least in part,
to plausible increases in the cellular proliferation and higher metabolic
capacity, the forestomach would be expected to show comparatively
higher DNA adduct levels and increases in the lacZ mutant frequency.
However, further studies are needed to conclusively deﬁne the mecha-
nisms underlying the similarities and differences in the responses of
forestomach and glandular stomach to oral PAH exposures.
In alignmentwith the observed levels of DNA adducts and induction
of mutations in the glandular stomach, analysis of all differentially
expressed genes and perturbed biological pathways in the forestomach
revealed activation of the DNA damage response. The cellular DNA
damage response to BaP exposure is regulated by p53 (Park et al.,
2006), a transcription factor that suppresses tumor formation by
modulating the expression of genes involved in cell cycle control,
DNA repair, inﬂammatory modulators, and growth factors. Our previ-
ous work has shown that the p53-regulated DNA damage response is
a primary pathway induced in the lungs and the liver of the same
mice as those studied here (Labib et al., 2012; Malik et al., 2012).
Genes within the p53-pathway exhibited a dose-dependent response
in the liver and lung, indicating the important role of p53 mediated
responses in coping with increasing amounts of DNA damage in these
tissues. Analysis of the forestomach transcriptome revealed alteration
of 21 p53-responsive genes (Fig. 2) in all of the doses combined.
Seven of these genes are directly involved in the DNAdamage response,
including the cell cycle regulatory genes cyclin dependent kinase inhib-
itor 1a (Cdkn1a) and cyclin-G1 (Ccng1), the DNA repair enzyme O-6-
methylguanine-DNA methyltransferase (Mgmt), and pro-apoptotic
genes Pmaip1, Trp53inp1, Trp3, and Trp73. The p53 transcription factor
was ranked 47th of 139 upstream regulators in the analyses conducted
here (see Supplementary Table 3). These results imply that the DNA
damage and activation of DNA repair mechanisms may be involved in
the onset and progression of cancer in the forestomach; however,
additional perturbations of other biological processes such as activa-
tion of immune response, and antigen processing and presentation
pathways are likely contributing to the development and progression
of forestomach tumors.
BaP activates antigen processing and presentation pathway
The other predominantly affected pathways in the BaP-exposed
forestomach involved the activation of genes involved in immun-
oproteasome activation, immune response, inﬂammatory response,
and antigen presentation. Speciﬁcally, signiﬁcant enrichment was ob-
served for MHC class genes involved in antigen processing and presen-
tation (Table 2). MHC molecules (classes I and II) are cell surface
glycoproteins that are necessary for the presentation of peptide antigens
to T lymphocytes, including T helper cells, cytotoxic T lymphocytes, and
NKT cells (Garcia-Lora et al., 2003). Antigenic peptides are generated
fromdegraded endogenous proteins during lysis or degradation of an in-
vading pathogen's cellular components by specialized multi-catalytic
Fig. 3. Activation of the immunoproteasome in the BaP exposed forestomach. Western blot analysis conﬁrming the expression of immunoproteasome subunits β1i and β2i and
proteasome subunits β1 and β2 in the Muta™Mouse forestomach exposed to 25 (green), 50 (blue), and 75 (red) mg/kg-bw/day BaP. The band intensities were normalized to
β-actin. *P ≤ 0.1, **P ≤ 0.05.
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Gregerson, 2012). Antigen presentation is the mechanism by which
MHC classmolecules bind antigens in the formof peptides on the surface
of bacterial or virus-infected cells and present them for recognition and
removal by the immune cells. Activated MHC class I molecules in nucle-
ated cells and MHC class II molecules on antigen presenting cells and
lymphocytes initiate activation of cytotoxic T lymphocytes and NKT
cells (class I), and T helper cells (class II). Thus, initiated T
cell-mediated signaling leads to a cascade of events ranging from cyto-
kine production, cellular proliferation, and target cell lysis (Weltzien
et al., 1996). Excessive T cell activation and cytokine production
will ultimately lead to apoptosis of cells probably consisting of cellu-
lar debris or chemical metabolites. Phagocytic engulfment of such
damaged cells will ultimately lead to the efﬁcient removal of the threat.
Various chemicals trigger an immune response via T cell activation
(Weltzien et al., 1996). Several studies have demonstrated the activa-
tion of T cells following exposure to BaP. For example, peritoneal mac-
rophages from mice exposed to BaP are shown to have an increased
ability to present MHC class II antigens (Myers et al., 1987). Anderson
et al. (1995) showed that AhR binding and phase I metabolism of
dimethylbenz(a)anthracene (another immunogenic PAH) is essential
for the induction of immune response involving CD8+T cells that is me-
diated byMHC class Imolecules in C3G/HeNmice. Transcriptomic proﬁl-
ing of peripheral blood mononuclear cells from healthy 25–30 year-old
non-smoking humans exposed for 20 h to three concentrations
(10-fold dilution series) of eight genotoxic carcinogens (4-hydroxy-2-
nonenal, malondialdehyde, acrylamide, 2-amino-3-methyl-3H-imidazo
[4,5-F]quinolone, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine,
aﬂatoxin B1, dimethylnitrosamine, and BaP) and three non-genotoxic
carcinogens (ethanol, polychlorinated biphenyl 153, and 2,3,7,8-
tetrachlorodibenzo-p-dioxin), showed that genes related to immune
response activation were uniquely found in the transcriptomic ﬁnger-
prints associated with eight genotoxic carcinogens, including BaP
(Hochstenbach et al., 2012). These results suggest that this type of
MHC class-induced response is common to a diverse array of xenobiotics,
and they raise important questions about the role of immune responses
in the recognition and removal of toxicants.MHC class I-mediated detoxiﬁcation of BaP
Cellular debris arising from the degradation of invading pathogens
generates antigenic peptides that are bound by MHC molecules and
presented to the immune cells for recognition and removal by the
phagocytes; however, it isn't clear why or how xenobiotics, or BaP
in particular, stimulate this response. What is clear is that the metab-
olism of PAHs is a prerequisite for activation of the immune response
(Anderson et al., 1995). Therefore, one possibility is that the accumula-
tion of DNA- or protein- reactive metabolites stimulates the generation
of antigenic peptides. The initial metabolism of BaP involves its oxida-
tion to epoxides bymembers of the cytochromeP450 family of enzymes
(IARC, 2012) that are further metabolized by epoxide hydrolases into
reactive BaP diol epoxides that can accumulate if not removed immedi-
ately. Downregulation of the phase II enzymes sulfotransferase family
1E member 1 and UDP-glucuronosyltransferase 2 family polypeptide
B34, which conjugate a sulfonyl group and glucuronic acid to electro-
philic phase I BaP metabolites, respectively, that was observed in the
forestomach of mice treated with high doses of BaP, could contribute
to the accumulation of hydrophobic reactive metabolites. If the metab-
olites are not cleared efﬁciently, they can form covalent adducts with
DNA and protein, the latter of which can induce BaP-speciﬁc antibody
production and immune response (Schellenberger et al., 2012). BPDE
can also bind the tripeptide glutathione (GSH), the most abundant
cellular antioxidant, leading to its depletion. Glutathione-s-transferases
(GST) mediate the formation of GSH–BPDE adducts by catalyzing the
binding of the sulfhydryl group of GSH to electrophilic BaP metabolites
(Dostal et al., 1988; Singh et al., 2004). Although the process of GSH con-
jugation effectively decreases the cellular pool of reactive BaP metabo-
lites, excessive binding of GSH to BPDE depletes the cellular pool of
free glutathione by 20 to 30% (Romero et al., 1997), and this can signal
increased activation of MHC class I antigen presentation (Makhadiyeva
et al., 2012). MHC molecules can bind these GSH–BPDE adducts or
BPDE directly and present them to phagocytes for their ultimate removal.
In toto, these arguments suggest that activation of MHC class I molecules
in the forestomach following oral BaP exposure serves primarily as a
detoxiﬁcation mechanism.
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BaP-treated mice appears to involve the immunoproteasome. The
primary role of the normal proteasomal degradation machinery is
the removal of abnormally folded proteins, peptides, cellular debris,
and adducted proteins (Hill et al., 2007; Sommerburg et al., 2009).
The immunoproteasome is a specialized proteasome complex activated
during an immune response that plays a speciﬁc role in the generation
of peptides that can ﬁt into MHC class I molecules, leading to the
proteasome-mediated degradation of cellular debris (Ferrington and
Gregerson, 2012; Krüger andKloetzel, 2012). Signiﬁcant and speciﬁc in-
creases in the expression of genes encoding the β1i and β2i subunits
(Psmb9 and Psbm10, respectively) and the corresponding protein
products (in the higher dose groups), supports the idea that immune
response-mediated removal of BaP plays amajor role in the forestomach.
In support of this, Schellenberger et al. (2012) showed that BaP-peptide
adducts induce the production of BaP-speciﬁc antibodies, whereas BaP
bound to bulky proteins results in an immune response directed
primarily against the protein rather than against BaP (Grova et al.,
2009). Antibodies generated against the peptide adduct complexes
are able to sequester BaP and its metabolites, resulting in reduced
excretion in the urine and feces (Schellenberger et al., 2012). These re-
sults collectively suggest that the immune response is a predominant
route bywhich BaP is detoxiﬁed in the forestomach, and that this process
involves activation of the immunoproteasome and immune response.
Fig. 4 shows the systematic arrangement of differentially expressed
genes in the BaP treated forestomach depicting the sequential activation
of the aforementioned processes that we propose lead to the removal of
BaP.
Human relevance
In order to investigate the relevance of gene expression changes in the
rodent forestomach to effects that relate to human health, we conducted
meta-analyses of the altered gene sets (Fig. 1, antigen processing and
presentation, immune response, chemotaxis, and keratinocyte differenti-
ation) using the NextBio HumanDisease Atlas Tool. The analysis revealed
a strong similarity between the dataset of the present study and genes
altered during human bacterial infectious diseases, parasitic disease,
respiratory disease, and viral infectious disease (Supplementary Table
4), supported by 85, 82, 27, and 117 studies, respectively. Melo and
Ruvkun (2012) used the nematode Caenorhabditis elegansmodel to dem-
onstrate that exposure to chemicals/xenobiotics or pathogens leads to
disruption of the same essential cellular activities such as mitochondrial
function, ribosome activities, protein translation, mRNA processing, etc.
These disruptions collectively serve as the physiological cues that lead
to activation of defense mechanisms, including detoxiﬁcation pathways
and immune responses. The results presented here suggest that the rec-
ognition and removal of BaP and/or its reactive metabolites from the
forestomach involves the same pathogen recognition mechanisms that
defend the host against microbial attack.
The other highlight of the present dataset is the signiﬁcant
upregulation of a large number of genes involved in keratinocyte differ-
entiation (Table 2), especially at the 50 and 75 mg/kg-bw/day doses
(Fig. 1). We observed dose-dependent increases in the expression of
numerous keratins including Krt6a, Krt6b, Krt12, Krt17, and Krt18, as
well as factors that are involved in the promotion of keratinocyte differ-
entiation, such as small proline-rich proteins Sprr1b, Sprr2a2, Sprr2d,
Sprr2e, Sprr2g, Sprr2h, Sprr2i, and Sprr2k. Analysis of this gene set in
the NextBio Human Disease Atlas Tool showed strong similarities be-
tween the BaP-exposed forestomachs and malignant tumors of the in-
testine and gastric cancers in humans (Table 1).
In the forestomach, the transformation of cuboidal epithelial cells
into stratiﬁed squamous cells, which produce large amounts of keratins,
is the ﬁrst indication of initiation of carcinogenic events (Kossoy et al.,
2006). The process is referred to as keratinocyte differentiation and is
routinely observed during the transformation of stomach epithelialcells in adenocarcinomas caused by Helicobacter pylori (H. pylori) infec-
tion in humans (where chronic infection eventually leads to intestinal
metaplasia) in humans. Keratins in squamous epithelia serve to protect
the cells from injury and are regulated bymany cancer-promoting stimuli
to promote cell growth, survival, andmotility. Excessive levels of keratins
are strongly associated with the development of various human cancers
(Cao et al., 2011;Mosca et al., 2010; Somji et al., 2008) and are correlated
with poor clinical outcome (Ide et al., 2012). A thick layer of keratin is
noted on pre-malignant papillomas and on the epithelial surface of the
forestomach in BaP fed mice (Rigdon and Neal, 1966, 1969). Enhanced
keratinocyte differentiation and dysplasia are also observed in mice
exposed to dimethylbenz(a)anthracene (Kossoy et al., 2006) via feed.
Dimethylbenz(a)anthracene, an alkyl-substituted PAH, has also been
shown to induce similar carcinogenic effects in the forestomach of ex-
posedmice. In another study, Shi et al. (2010) found squamous cell carci-
noma in the preputial gland duct of Cyp1a1 and Cyp1b1 double knockout
mice following 12 weeks of oral BaP exposure that showed increased
levels of keratin deposition. In a follow-up study using microarrays,
these authors further demonstrated a signiﬁcant upregulation of genes
associated with keratinization in the preputial gland duct after 8 weeks
of exposure to BaP (Gálvez-Peralta et al., 2013). Although the role of
keratinocyte differentiation in carcinogenesis is not well understood,
Krt17 is known to positively regulate cell size and growth of keratinocytes
by binding to the adaptor protein 14-3-3 sigma and by stimulatingmTOR
signaling (Kim et al., 2006), which is involved in sustaining proliferative
signaling (a hallmark of cancer) (Hanahan and Weinberg, 2011). These
results collectively suggest that the key events leading to cancer are dif-
ferent in the forestomach and somewhat distinct from those observed
in other tissues, and include a strong immune response, persistent in-
ﬂammation, and initiation of keratinocyte differentiation. The strong sim-
ilarities observed between our dataset and those that are associatedwith
human stomach diseases, including cancers, provides evidence for use of
forestomach tumor data for assessments of human cancer risks associ-
ated with PAHs such as BaP.
An acknowledged shortcoming of the present study is that we did
not compare the transcriptomic responses between the forestomach
and glandular stomach, target and non-target organs for BaP-induced
cancers in rodents. Although the rodent glandular stomach is analogous
to the human gastric stomach, it does not develop tumors after expo-
sure to high doses of BaP (oral, intraperitoneal, or intramammary
route) that induce signiﬁcant DNA damage. Out of the 570 two-year
rodent cancer bio-assays conducted by the National Toxicology Program
(NTP), very few resulted in glandular stomach cancers (Chandra
et al., 2010). Therefore, it is quite possible that we will see different
transcriptomic proﬁles in the two tissues; however, we do expect to
see similar changes in genes that respond to DNA damage. Our previous
work comparing transcriptomic responses in lung and liver tissues ex-
posed to BaP have rightly pointed out the distinctmodes of actionwith-
in each tissue that relate to their inherent function. For example, despite
comparable levels of DNA damage between the lung and liver tissues,
our ﬁndings showed a rather subtle transcriptomic response in the
liver (target organ for carcinogenesis by BaP) that was not directly
suggestive of cancer even at the higher doses. On the other hand,
transcriptomics did reveal changes in the expression of important
DNA damage responsive genes consistent with the observed DNA ad-
ducts in the liver. In the lung tissue, a dramatic response was observed
at all doses tested, with incremental dose-related changes related to
carcinogenesis. These results suggest that the inherent functions of
tissues, and the concomitant balance between biological pathways
leading to enhanced cellular proliferation and pathways leading to cell
death, play important roles in chemically-induced carcinogenesis.
Based on these arguments we should expect to see 1) changes in the
expression of DNA damage response genes in the glandular stomach
similar to those observed in the forestomach, lungs (Labib et al., 2012),
and liver (Malik et al., 2012) of mice exposed to BaP, and 2) parallel acti-
vation of cellular proliferation and cell death genes. In addition, in
Fig. 4. Molecular relational network of genes modulated by BaP in the forestomach using MetaCore for all three doses. A network is a graphical representation of the molecular
relationships between molecules. Biological relationships between two molecules are represented by a line; green lines denote positive effect, red lines denote negative effect,
and gray lines represent unspeciﬁed effect. Biological processes are presented in causal order of BaP-induced damage removal and eventually carcinogenic transformation. Hexagons
represent physical and functional interactions: B— binding,+P— phosphorylation, Z— catalysis, TR— transcription regulation, IE— inﬂuence on expression, and CS— complex subunit.
The processes include genes that were differentially regulated in the 25 mg/kg-bw/day (green rectangle), 50 mg/kg-bw/day (blue rectangle), and 75 mg/kg-bw/day (red rectangle) dose
groups.
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glandular stomach tumors (i.e. the inhibition of gastric acid secretion
leading to hypergastrinemia and hyperplasia (Chandra et al., 2010)),
we may expect to observe induction of pathways counteracting these
processes. Since due to lack of available tissue, the present study could
not provide evidence to substantiate the aforementioned assertions,
additional experiments are warranted.
Conclusion
We present a model for the rodent forestomach responses to BaP
and propose key pathways that we believe to underlie BaP-induced
forestomach carcinogenesis. We ﬁnd that the gene expression signa-
tures in the BaP-exposed forestomach are broadly similar to human
cancers of the gastrointestinal tract, and that general detoxiﬁcation
pathways including sulfation and glucuronidation are negatively regu-
lated in the BaP-exposed forestomachs, potentially resulting in the
accumulation of BaP and BaP metabolites. Excessive accumulation of
DNA- or protein-reactive metabolites then serve as cues leading to the
activation of other detoxiﬁcation/defense mechanisms such as the
immunoproteasome, antigen processing and presentation pathways, T
cell activation, cytokine-mediated inﬂammation, and interferon γ sig-
naling. Exposure to very high levels of BaP (75 mg/kg-bw/day) leads
to unremitting activation of immune responses and inﬂammation, and
ultimately activation of keratinocyte differentiation, an important
biological alteration that is considered a hallmark of forestomach carci-
nogenesis. Despite functional and histological differences between the
rodent forestomach and the human stomach, there appear to be com-
mon tissue-speciﬁc alterations in core cellular responses to invading
pathogens/toxicants and the identity and functions of individual genes
that are disrupted in the forestomach of mice exposed to BaP for
28 days are consistent with the development of human cancers of the
esophagus and gut. Thus, our results provide support for the relevance
and use of rodent forestomach tumor data in human cancer risk evalu-
ation. More studies involving testing of other known forestomach
carcinogenswith awide range of doses and time pointswill be necessary
to further conﬁrm these ﬁndings.
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